Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.11 | 0.18 | 0.04 |
| FCF Yield | -17.89% | -18.99% | -10.10% | -23.31% |
| EV / EBITDA | -4.60 | -3.81 | -6.12 | -2.46 |
| Quality | ||||
| ROIC | -43.02% | -54.76% | -32.24% | -41.83% |
| Gross Margin | 100.00% | -321.02% | 57.39% | 79.08% |
| Cash Conversion Ratio | 0.86 | 0.77 | 0.72 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -44.56% | -52.68% | 19.06% | -12.75% |
| Free Cash Flow Growth | -25.81% | -95.56% | -72.32% | -84.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.35 | 1.17 | 0.53 |
| Interest Coverage | -98.17 | -137.76 | -276.35 | -26,576.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.11 | 0.00 |
| Cash Conversion Cycle | 0.00 | -499.61 | -10,062.18 | -1,315.55 |